The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
November 4th 2024
Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.
Adjuvant T-DM1 Approved in China for HER2+ Early Breast Cancer
January 24th 2020China’s State Administration of Drug Administration has approved ado-trastuzumab emtansine for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease following a neoadjuvant trastuzumab-based regimen.
Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer
January 17th 2020Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.
Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer
January 4th 2020Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.